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Due to the ageing of the population and the sharp
increase in life expectancy, cancer diagnosed in the
elderly population is rising and it has become an
increasingly common problem in the Western world.
According to the National Cancer Institute (NCI), for all
cancers combined, the incidence rate in people 65 and
over is 10 times higher than the rate for younger people,
and the mortality is 16 times higher. The number of
people in the United States who are 65 and older is
expected to double by year 2030.
A study published in 1999 in the New England Journal
of Medicine found that while 63% of people in the gen-
eral population age 65 or older had cancer, only 25% of
patient in that age group were represented in clinical
trials.
The cut-off point at which an adult is considered
‘elderly’ has not been well defined. Usually, age 70 years
is considered a reference point and is commonly used in
clinical trials in oncology.
One of the most intriguing aspects of ageing is how
different the ageing process is from person to person;
the basis for this variation is largely unknown.
Clinical trials are generally used for the clinical devel-
opment on new drugs/strategies. They are divided in
three consecutive phases (I, II and III). The firsts two
aim to characterize the action and to archive all knowl-
edge necessary for better mange the experimental drugs.
For all these reasons it is important to allow the inclu-
sion of selected people without comorbidities that can
interfere with the results. In contrast, phase III trials,
considered the last step before registration, aim to
demonstrate the efficacy/utility of the experimental
drug/strategies on a number of patients representing the
whole population of patients for a selected pathology.
If it is tolerable to limited the participation of elderly
patients, for their frailty, comorbidities or different
metabolism, in the inclusion of phase I or dose finding
and Phase II trials it is not acceptable to exclude them
in the large phase III.
Furthermore, it is now clear that Chronologic age can-
not be used to predict the degree of comorbidity and of
functional deterioration of the single individual up to
age 85 at least; Performance status, which takes into
account level of activity, ambulation, and ability to care
for oneself-and the presence of comorbid conditions
that may be exacerbated by treatment are more reliable
criteria for clinical trial eligibility than age.
In conclusion age alone should never make a patient
ineligible for a trial.
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